HTFL

HeartFlow, Inc. develops and commercializes non-invasive cardiovascular diagnostic solutions powered by artificial intelligence and advanced computational modeling. Headquartered in Mountain View, California, the company transforms standard coronary computed tomography angiography (CCTA) scans into personalized 3D models that analyze blood flow and assess the impact of blockages on coronary arteries. Its flagship product, the HeartFlow FFRct Analysis, enables physicians to diagnose and treat coronary artery disease without the need for invasive procedures, offering a precision medicine approach to cardiovascular care. The company serves hospitals, health systems, and clinics across the United States, Europe, and Japan, having analyzed over 350,000 patients since its commercial launch. HeartFlow generates revenue through a per-case reimbursement model from both private and public payers, including Medicare coverage established in 2021. The company employs approximately 700 people globally and operates research and development facilities in the United States and the United Kingdom. In recent years, HeartFlow has expanded its product portfolio beyond coronary artery disease to include the HeartFlow Planner, a surgical planning tool for structural heart interventions, and continues investing in AI-driven innovations. The company completed its initial public offering in October 2021, trading on the NASDAQ under the ticker symbol HTFL.